Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: a randomized, double-blind, cross-over investigation in obese persons by Andersson, U et al.
ORIGINAL ARTICLE
Effects of rose hip intake on risk markers of type 2 diabetes and
cardiovascular disease: a randomized, double-blind, cross-over
investigation in obese persons
U Andersson
1, K Berger
1,AH o ¨gberg
2, M Landin-Olsson
3 and C Holm
1
BACKGROUND/OBJECTIVES: In studies performed in mice, rose hip powder has been shown to both prevent and reverse
high-fat diet-induced obesity and glucose intolerance as well as reduce plasma levels of cholesterol. The aim of this study was
to investigate whether daily intake of rose hip powder over 6 weeks exerts beneﬁcial metabolic effects in obese individuals.
SUBJECTS/METHODS: A total of 31 obese individuals with normal or impaired glucose tolerance were enrolled in a
randomized, double-blind, cross-over study in which metabolic effects of daily intake of a rose hip powder drink over 6 weeks
was compared with a control drink. Body weight, glucose tolerance, blood pressure, blood lipids and markers of inﬂammation
were assessed in the subjects.
RESULTS: In comparison with the control drink, 6 weeks of daily consumption of the rose hip drink resulted in a signiﬁcant
reduction of systolic blood pressure ( 3.4%; P¼0.021), total plasma cholesterol ( 4.9%; P¼0.0018), low-density lipoprotein
(LDL) cholesterol ( 6.0%; P¼0.012) and LDL/HDL ratio ( 6.5%; P¼0.041). The Reynolds risk assessment score for
cardiovascular disease was decreased in the rose hip group compared with the control group ( 17%; P¼0.007). Body weight,
diastolic blood pressure, glucose tolerance, and plasma levels of high-density lipoprotein (HDL) cholesterol, triglycerides,
incretins and markers of inﬂammation did not differ between the two groups.
CONCLUSIONS: Daily consumption of 40g of rose hip powder for 6 weeks can signiﬁcantly reduce cardiovascular risk in obese
people through lowering of systolic blood pressure and plasma cholesterol levels.
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INTRODUCTION
The incidence and prevalence rates of type 2 diabetes mellitus
(T2DM) is increasing dramatically all over the world.
1 Current
estimates predict that 439 million people worldwide will be
affected by 2030,
1 and this ﬁgure does not take into account the
large number of people in prediabetic states, that is, glucose
intolerance accompanied or not by obesity. Obesity is a very strong
risk factor for the development of T2DM and approximately 90% of
people diagnosed with T2DM are either overweight or obese. The
mechanisms whereby obesity leads to the development of T2DM
are poorly understood, but dysfunction of the expanding adipose
tissue, leading to ectopic lipid deposition, and low-grade inﬂam-
mation are believed to be key events linking obesity to T2DM.
2,3 An
inﬂammatory reaction may also be triggered via changes in the gut
microbiota resulting in endotoxemia.
4 Besides hyperglycemia,
T2DM is characterized by elevated levels of circulating lipids and
hyperlipidemia is causally linked to the cardiovascular compli-
cations of T2DM.
5 Owing to the pathophysiological role of lipids in
the development of both T2DM and its complications, diabetes care
is strongly focused on the strict regulation of the plasma levels of
both glucose and lipids.
It has been estimated that the development of diabetes to a large
extent is preventable by adopting a healthy diet and increasing
physical activity (International Diabetes Federation, http://www.idf.
org/prevention). Thus, there is an urgent need for the identiﬁca-
tion and development of foods with documented effects on the
prevention of development of obesity, T2DM, and associated
diseases and complications. Rose hip is the pseudofruit of the rose
plant.
6 The fruit is rich in antioxidants, such as ascorbic acid,
phenolic compounds and carotenoids. It has been used in
traditional medicine for almost a century for its high content of
ascorbic acid. During the last decade, the anti-inﬂammatory
properties of rose hip have been documented in several studies
and it has been used successfully to ameliorate symptoms in
patients suffering from osteoarthritis, rheumatoid arthritis and
lower-back pain.
7- -11 Recently, two independent studies, per-
formed in two different strains of mice, demonstrated that rose
hip exerts anti-obese and anti-diabetic effects. Ninomiya et al.
12
reported that the administration of an acetone extract of fruits and
seeds from dog rose (Rosa canina) prevented body-weight gain in
mice fed with a normal chow diet. At least some of the effects
could be ascribed to trans-tiliroside, a constituent of the extract, as
administration of this reduced body-weight gain and improved
glucose tolerance. In the other study, performed in our laboratory,
the high-fat fed C57BL/6J mouse model, simulating human
obesity and insulin resistance, was used to demonstrate that the
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www.nature.com/ejcnadministration of rose hip powder was able to both prevent and
reverse diet-induced obesity and glucose intolerance.
13 In both
studies, it was ruled out that decreased food intake accounted for
the effects. Furthermore, in both studies rose hip administration
was also shown to exert lipid-lowering effects.
The aim of the present study was to investigate whether
the beneﬁcial metabolic effects observed in response to rose hip
intake in mice could be reproduced in a human study. To this end,
we performed a randomized, double-blind, cross-over study in
which either a rose hip drink or a control drink was administered
for 6 weeks to obese individuals with or without glucose intole-
rance. Primary endpoints were body weight, glucose tolerance,
and fasting levels of glucose and insulin. Secondary endpoints
were plasma total cholesterol, plasma low density lipoprotein
(LDL) cholesterol, blood pressure and markers of inﬂammation.
SUBJECTS AND METHODS
Participants
The study was carried out in the period April 2009 to February 2010 at the
Department of Clinical Sciences, Lund University Hospital. Study partici-
pants were recruited from the registry of obese patients at the
Endocrinology Clinic. The patients of this registry had previously
participated in a time-limited weight reduction program at the clinic.
Despite poor results in terms of weight reduction, they were not interested
in gastric bypass surgery, but had expressed their interest in forthcoming
weight reduction programs and food intervention studies. Inclusion criteria
were body mass index430, willingness to participate in the study, comply
with the daily intake of the drinks and the recommended energy intake
during the course of the study. Exclusion criteria were diabetes, previous or
ongoing insulin treatment, abnormal thyroid, liver or kidney status, known
gastro-intestinal disorder, pregnancy and suspected allergy to ingredients
of the control and test drinks. A total of 34 subjects, randomly selected
from the registry, were assessed for eligibility (Supplementary Figure 1)
and 31 of these (23 women and 9 men; age range 33- -75, mean age 56,
mean body mass index 35) signed the written consent and entered as
participants in the study. Seven of the participants had impaired glucose
tolerance, based on the results of the oral glucose tolerance test, nine were
on hypertensive therapy and eight were on lipid-lowering medication with
statins. There were no reported changes in medication during the study.
Baseline characteristics of the participants at the start of the study were
similar between individuals receiving control ﬁrst and rose hip second, and
individuals receiving rose hip ﬁrst and control second, except for a
signiﬁcantly higher body weight in the group that was randomized to start
with the rose hip drink (Table 1).
Study protocol
The study design was that of a randomized, double-blind, cross-over study
with a 6-week treatment period and a 2-week wash-out period
(Supplementary Figure 1). The participants were randomly assigned to
start with either the control or the test drink. In addition to the
consumption of the control or test drink (5dl per day), the participants
were instructed to restrict their caloric intake to 75% of resting metabolic
rate  1.3, where resting metabolic rate was calculated according to the
equation provided by World Health Organization. Examples of daily menus,
adhering to the national guidelines of macro- and micronutrient intake,
were provided. The participants visited the clinic every 2 weeks to obtain
test drinks for the following 2 weeks, measure body weight, give blood
samples and report adverse effects. Intake was conﬁrmed by questions to
the participants at each visit at the clinic. At the start and end of each
period a meal-based glucose tolerance test was performed. Participants
visited the clinic on a total of nine occasions. Medical supervision and
biological sampling took place at Lund University Hospital, Lund, under the
responsibility of M.L-O. The study was approved by the Ethics Committee,
Lund, Sweden (Dnr 2009/11) and was in accordance with the Helsinki
Declaration of 1975, as revised in 1983.
Control and test drink
The fruit from rose hip (Rosa canina) was imported from Chile. In a two-
step procedure, seeds were removed and the remainder of the fruit was
ground and mixed with apple juice, citric acid solution and sugar in a
mixing tank with stirring. The mixture was preheated with a heat
exchanger to 551C and degassed before heating to 921C. After 95s the
mixture was cooled to 201C and stored in an aseptic tank until packaged in
500ml aseptic Tetra Brik packages (Tetra Pak, Lund, Sweden). The control,
consisting of apple juice, white grape juice, citric acid solution and sugar,
was produced with the same procedure. Test drinks were analyzed at
Euroﬁns (Lidko ¨ping, Sweden) for content of raw protein, raw fat, water,
Table 1. Characteristics of study participants at time of inclusion
All participants Individuals receiving control
ﬁrst and rose hip second
Individuals receiving rose
hip ﬁrst and control second
Age (years) 57±2 (37- -75)
a 59±3 (42- -75) 55±3 (37- -71)
Female (n¼22) 59±2 (42- -75) 61±3 (42- -75) 57±3 (44- -69)
Male (n¼9) 52±4 (37- -71) 53±5 (48- -67) 52±7 (37- -71)
Body weight (kg) 102.9±2.8 (80.4- -135.8) 95.4±3.8 (80.4- -129.5) 110.9±3.3 (83.6- -135.8)
BMI (kg/m
2) 35.3±0.6 (29.5- -44) 35.5±0.6 (29.5- -38.9) 37.2±0.9 (31.5- -44)
Systolic BP (mmHg) 129±3 (105- -170) 130±3 (105- -152) 128±4 (105- -170)
Diastolic BP (mmHg) 77±2 (60- -110) 74±1 (60- -84) 80±3 (60- -110)
FP-glucose (mmol/l) 5.6±0.1 (4.5- -7.3) 5.4±0.1 (4.5- -6.8) 5.9±0.2 (4.5- -7.3)
FP-insulin (mIU/l) 11.4±0.7 (6- -22) 10.6±0.8 (6- -17) 12.3±1.2 (6- -22)
FP-cholesterol (mmol/l) 5.4±0.2 (3.8- -8.9) 5.6±0.4 (3.8- -8.9) 5.1±0.2 (4.0- -6.6)
FP-LDL cholesterol (mmol/l) 3.2±0.2 (1.6- -6.4) 3.5±0.3 (2.1- -6.4) 2.9±0.2 (1.6- -4.1)
FP-HDL cholesterol (mmol/l) 1.4±0.07 (0.6- -2.4) 1.4±0.09 (0.6- -2.2) 1.4±0.1 (0.7- -2.4)
FP-TG (mmol/l) 1.6±0.1 (0.7- -3.3) 1.6±0.2 (0.7- -3.1) 1.6±0.2 (0.8- -3.3)
P-ASAT (mkat/l) 0.46±0.05 (0.22- -1.90) 0.48±0.09 (0.22- -1.90) 0.43±0.02 (0.29- -0.61)
P-ALAT (mkat/l) 0.49±0.07 (0.19- -2.30) 0.52±0.12 (0.19- -2.30) 0.47±0.05 (0.25- -0.84)
P-ALP (mkat/l) 1.16±0.05 (0.25- -0.84) 1.24±0.06 (0.76- -1.70) 1.08±0.07 (0.52- -1.60)
P-GT (mkat/l) 0.56±0.07 (0.22- -1.70) 0.49±0.08 (0.22- -1.70) 0.62±0.10 (0.25- -1.50)
P-bilirubin (mmol/l) 9±1 (3- -21) 10±1 (4- -21) 7±1 (3- -16)
Abbreviations: BMI, body mass index; BP, blood pressure; FP, fasting plasma; HDL, high density lipoprotein; LDL, low density lipoprotein; P-ALAT, plasma-alanine
aminotransferase; P-ALP, plasma-alkaline phosphatase; P-ASAT, plasma-aspartate aminotransferase; P-GT, plasma-glutamyltransferase; TG, triglycerides.
aMean±s.e.m (min.- -max.), n¼30- -31.
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The recipe and results of analyses of the drinks are shown in Table 2.
The drinks were designed to have equal amounts of simple sugars and the
analysis of the ﬁnal products showed a difference of o10%.
Meal-based tolerance test
Glucose tolerance was assessed by measuring plasma glucose at 0, 30, 60,
90 and 120min, and plasma insulin at 0 and 30min following the ingestion
of a carbohydrate-rich breakfast. Participants came to the clinic at 0800
hours in fasting condition and had a breakfast corresponding to 521kcal
and 100g carbohydrates, of which 38g were disaccharides (26 sucrose)
and 20.5g monosaccharides. Blood samples were drawn in two separate
tubes, one with Trasylol (aprotinin, Bayer AG, Leverkusen, Germany) and
one with DPP-4 inhibitor, and centrifuged (41C) immediately after
sampling. Plasma was frozen on dry ice and stored at  801C until analysis.
Body weight and blood pressure
Body weight was measured using an electronic body weight scale (Tanita,
Tanita Europe BV, Amsterdam, The Netherlands), which was calibrated
regularly. Blood pressure was measured using a mercury sphygmoman-
ometer in the sitting position after 5min resting. The mean of three
consecutive measurements was recorded.
Laboratory analyses
Except for GLP-I, GIP, adiponectin and PAI-I, all blood and plasma analyses
were conducted at the accredited clinical chemistry laboratory at Lund
University Hospital. C-reactive protein (CRP) was measured using a high-
sensitivity assay. PAI-I was analyzed using a high-sensitivity assay available
at the accredited blood coagulation laboratory at Lund University Hospital,
Malmo ¨. GLP-I and GIP was analyzed using Luminex Technology (LX200,
Luminex Corporation, Austin, TX, USA). Adiponectin was analyzed with
ELISA (Millipore Corporation, Billerica, MA, USA).
Statistical analyses
All data are shown as means (95% conﬁdence intervals) with s.e.m. To
determine the differences in the measured variables following intake of
the control and rose hip drink, paired t-tests were used when the data was
Gaussian distributed according to D’agostino and Pearson omnibus
normality test. When not normally distributed, Wilcoxon matched-pairs
signed rank test was used. Statistical analyses were performed using
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) and the
statistical software package SPSS for Windows (SPSS Inc., Chicago, IL, USA).
Po0.05 was considered signiﬁcant.
RESULTS
Dietary intake and adverse effects
Both drinks were tolerated well by the participants, but mild
gastrointestinal problems were reported in both the groups, more
frequently in the rose hip group (11 compared with 2 in the
control group). Loose stools and ﬂatulence was the most
commonly reported adverse effect (eight in the rose hip group,
one in the control group), but obstipation was also reported (three
in the rose hip group, one in the control group).
Body weight and glucose tolerance
The sequence of the drink did not inﬂuence the outcome, so data for
each drink were pooled and referred to as control group and rose hip
group, respectively. Daily intake of the rose hip drink was found to
have no effect on body weight and body mass index (Table 3).
Furthermore, no effects were observed on HbA1c or fasting levels of
plasma glucose and insulin (Table 3), indicating that rose hip intake
had no effects on glucose tolerance or insulin sensitivity. Possible
effects on glucose tolerance were further assessed in meal-based
glucose tolerance tests. These showed no signiﬁcant differences
between the groups with regard to plasma glucose levels
(Supplementary Figure 2) or plasma insulin levels (Supplementary
Table 1). Also, there were no differences with regard to the incretin
response, assessed by the measurement of plasma levels of GLP-I
and GIP at 0 and 30min (Supplementary Table 1).
Plasma lipids and blood pressure
Intake of the rose hip drink was found to result in a small but
signiﬁcant reduction in plasma levels of total cholesterol ( 4.9%;
P¼0.0018), as well as LDL cholesterol ( 6.0%; P¼0.012),
compared the intake of the control drink (Figure 1). Plasma
high-density lipoprotein (HDL) cholesterol, on the other hand, was
not altered (Figure 1). The changes in cholesterol parameters were
reﬂected in a decrease in the LDL/HDL ratio ( 6.5%; P¼0.041) in
the rose hip group (Figure 1). Exclusion of the eight participants
who were on statin treatment in the analyses resulted in more
pronounced cholesterol-lowering effects of rose hip, that is, a
reduction of total cholesterol by 5.5% (P¼0.0039; n¼19) and a
reduction of LDL cholesterol by 8.6% (P¼0.0057; n¼19). In
contrast to cholesterol, no differences in plasma triglyceride levels
were found between the rose hip and the control group (Table 3).
Table 3. End-point values after the 6-week intervention period with
either the control drink (Control) or the drink containing rose hip
(Rose hip)
Control Rose hip P
Body weight (kg) 101.9±2.91 102.7±3.1 NS
BMI (kg/m
2) 36.6±1.0 35.9±0.9 NS
FP-glucose (mmol/l) 5.6±0.2 5.7±0.2 NS
FP-insulin (mIU/l) 12.5±0.9 12.5±0.9 NS
HbA1c (mmol/mol) 35±0.4 35±0.6 NS
TG (mmol/l) 1.5±0.1 1.5±0.1 NS
P-ASAT (mkat/l) 0.48±0.06 0.43±0.03 NS
P-ALAT (mkat/l) 0.49±0.07 0.54±0.06 NS
P-GT (mkat/l) 0.49±0.07 0.48±0.05 NS
P-ALP (mkat/l) 1.1±0.05 1.2±0.05 NS
P-bilirubin (mmol/l) 7.8±0.5 7.9±0.5 NS
CRP (mg/l) 3.7±3.01 3.8±3.6 NS
Adiponectin (mg/l) 16.4±1.7 14.9±1.5 NS
PAI-1 (IU/ml) 27.6±3.2 29.9±3.4 NS
Abbreviations: BMI, body mass index; CRP, C-reactive protein; FP, fasting
plasma; P-ALAT, plasma-alanine aminotransferase; P-ALP, plasma-alkaline
phosphatase; P-ASAT, plasma-aspartate aminotransferase; P-GT, plasma-
glutamyltransferase; TG, triglycerides. Mean±s.e.m, n¼25- -28.
Table 2. Recipe and analysis of test drinks
Control Rose hip
Ingredients (g per 1000g)
Apple juice concentrate 88 88
Grape juice concentrate 19.4 - --
Water 858.8 815.1
Citric acid solution 1.5 1.5
Sugar solution (65%) 32.3 15.4
Rose hip meal - - - 80
Energy (kJ per 1000g) 1318 1326
Analyses (g per 1000g)
Raw protein 0.9 3.0
Raw fat 1.3 3.2
Glucose 17 17
Fructose 32 33
Sucrose 26 19
Fiber, total ND 31
Fiber, insoluble ND ND
Fiber, soluble ND 31
Abbreviation: ND, non-detectable.
Metabolic effects of rose hip
U Andersson et al
587
European Journal of Clinical Nutrition (2012) 585- -590 & 2012 Macmillan Publishers LimitedIntake of rose hip was found to signiﬁcantly lower systolic blood
pressure, with no effect on diastolic blood pressure (Figure 2).
Systolic blood pressure was signiﬁcantly lower than that in the
control group even when the eight participants who were on
antihypertensive treatment were excluded from the analyses
( 3.7%; P¼0.04, n¼20). Applying the algorithm of the Reynolds
risk assessment score
14,15 to the data demonstrated a signiﬁcant
reduction (17%, P¼0.0075, n¼25) in 10-year risk of cardio-
vascular disease (Figure 3).
Inﬂammatory markers
In order to assess the possible effects of rose hip intake on low-
grade inﬂammation, we measured the plasma levels of CRP and
PAI-I, two markers of inﬂammation, and adiponectin, an adipokine
with anti-inﬂammatory properties. There were no signiﬁcant
differences between the groups for any of these markers (Table 3).
DISCUSSION
To the best of our knowledge, this is the ﬁrst study in humans
investigating the metabolic effects of dietary administration of rose
hip. Daily consumption of rose hip was found to signiﬁcantly
decrease plasma cholesterol and systolic blood pressure in obese,
non-diabetic individuals, whereas no effects on body weight,
glucose tolerance and markers of inﬂammation were observed. The
reduction in plasma cholesterol and systolic blood pressure was
estimated to lower the risk of developing cardiovascular disease by
17%, using the algorithm for Reynolds risk assessment score.
The magnitude of the lowering of plasma levels of LDL
cholesterol in the rose hip group, that is 6.0% compared with
the control, was within the range from 6 to 15% that has been
reported in the few long-term studies performed on cholesterol-
lowering effects of single foods
16- -19 and accords very well with
the 5% reduction considered realistic in real-world situations
when dietary saturated fat levels are low.
20 The observed decrease
in LDL cholesterol in the rose hip group is below the minimum of
8--9% required to see a reduction in total mortality, although it is
estimated to reduce the incidence of coronary heart disease by
14.5%.
21 With the exception of two individuals who had slightly
elevated cholesterol levels, the participants of the present study
had normal plasma cholesterol levels. Thus, the full potency of
rose hip to lower plasma cholesterol may not have been revealed
and a follow-up study in hyperlipidemic individuals seems
warranted. Cholesterol-lowering properties of rose hip have
previously been demonstrated in a study performed in high-fat
diet fed C57BL/6J mice.
13 In that study, the reduction in total
plasma cholesterol was shown to involve a reduction in both LDL
cholesterol and HDL cholesterol with a larger effect on LDL
cholesterol, resulting in a decreased LDL/HDL ratio. In the present
study, a very similar proﬁle of the cholesterol-lowering effects was
observed, with a signiﬁcant reduction in LDL cholesterol and LDL/
HDL ratio, and a smaller, in this case non-signiﬁcant, lowering of
HDL cholesterol. In a previous human study where a rose hip drink
was administered daily to hypercholesterolemic subjects for 6
weeks as a control to intake of the same drink supplemented with
Lactobacillus plantarum 299v, no cholesterol-lowering effects were
observed by rose hip alone.
22 The reason for the discrepancy
compared with the present study is not known, but it should be
pointed out that besides differences in the characteristics of
subjects, the dose of rose hip was only about 25% of that
employed in the present study. In another study where 5g of a
standardized rose hip powder (Hyben Vital) was administered
daily for 3 months to patients with osteoarthritis, total cholesterol
was reduced by 8.5%, indicating that lower doses of rose hip may
also promote lowering of plasma cholesterol if administered for
longer periods.
23 It should be pointed out, however, that besides
differences in dose and length of administration, also the
preparation of rose hip differs between studies, making compar-
isons difﬁcult. For instance, the powder used by Rein et al.
23
contains both the seeds and shells of the rose hip plant, whereas
only the shells were used in our study. The fact that the
cholesterol-lowering effects were exerted by both of these
preparations may indicate that the shells rather than the seeds
account for the cholesterol-lowering properties of rose hip.
The mechanism whereby rose hip is capable of reducing plasma
cholesterol is unknown. In the study performed in C57BL/6J mice,
the reduction in plasma cholesterol was accompanied by reduced
Figure 2. Systolic and diastolic blood pressure following 6 weeks of
intake of the control drink or the rose hip drink. Mean±s.e.m,
n¼28. *Po0.05.
Figure 1. Plasma total cholesterol, LDL cholesterol, HDL cholesterol
following 6 weeks of intake of the control drink or the rose hip drink.
The LDL/HDL ratio is shown in the inset. Mean±s.e.m, n¼27--28.
*Po0.05; **Po0.01.
Figure 3. Reynolds risk assessment score following 6 weeks of intake
of the control drink or the rose hip drink. Mean±s.e.m, n¼25.
**Po0.01.
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HMG-CoA reductase was unaltered, indicating that cholesterol
biosynthesis was unaffected.
13 It is possible that the high ﬁber
content of rose hip impairs the enterohepatic circulation of bile
acids by preventing their re-absorption, thereby promoting
increased synthesis of bile acids from cholesterol, that is, a
mechanism of action similar to that of the cholesterol-lowering
drug cholestyramin.
The observed decrease in systolic blood pressure (4mmHg) was
close to the median reduction observed in 27 pharmacological trials
estimated to result in decreases of the incidence of coronary heart
disease and stroke by 415% and 25%, respectively.
24 In a previous
study, no decrease in blood pressure in smokers was observed by
daily intake of rose hip for 6 weeks, whereas intake of the same rose
hip drink supplemented by Lactobacillus plantarum resulted in a
signiﬁcant reduction of systolic blood pressure.
25 The dose of rose
hip employed was about 25% of the dose in the present study,
which may explain why no effects were observed. The mechanism
whereby rose hip lowers systolic blood pressure is unknown. As for
the cholesterol-lowering effects, it could be speculated that the
high ﬁber content of rose hip at least partially accounts for the
effect. Consumption of the rose hip drink corresponded to a daily
intake of 31g of ﬁber. Two meta-analyses have concluded that an
increase in ﬁber intake of 10--15g per day for 8 weeks
was associated with a decrease in systolic blood pressure of
1--2mmHg.
26,27 Thus, the reduction of 4mmHg in the present
study is likely to be a result of the high ﬁber intake, although it may
very well be that other bioactive components than ﬁber contribute
to the blood pressure-lowering effects of rose hip.
Daily intake of rose hip had no effects on body weight or
glucose tolerance. This is in contrast to two previous studies
performed in mice, where dietary intake of rose hip potently
inhibited body-weight gain and also signiﬁcantly improved
glucose tolerance.
12,13 The reason for this discrepancy is not
known, but two obvious differences relate to the dose adminis-
tered and the metabolic status of the study population. Although
the daily intake of rose hip powder in the current study was high
compared with previous studies in humans (40 vs 5g
8,11,23,28), it
was much lower than that in the study in C57BL/6J mice, where
rose hip accounted for 30% of the daily food intake. The fact that
the participants of the current study, in contrast to the mouse
studies, were on an energy-restricted diet throughout the study
could have obscured effects on body weight and future studies in
a large number of overweight, or even lean, individuals on a non-
restricted diet would be of interest. Also, the present study,
designed to represent a ﬁrst proof-of-concept study of possible
metabolic effects of rose hip in humans, was performed in obese
individuals with no diabetes and with only a few glucose-
intolerant participants. This is in contrast to the high-fat fed
C57BL/6J mouse model, where obesity is accompanied by glucose
intolerance.
Several previous studies have demonstrated that the dietary
administration of rose hip to individuals with osteoarthritis and
rheumatoid arthritis exerts anti-inﬂammatory effects.
7,8,11,29 Obe-
sity and its associated diseases are considered to be states of low-
grade inﬂammation. However, we were unable to detect any
signiﬁcant differences with regard to two markers of systemic
inﬂammation, that is, CRP and PAI-I, or with regard to adiponectin,
an adipokine with anti-inﬂammatory as well as insulin-sensitizing
effects. Possibly the most obvious explanation for the lack of effect
on these markers is that the low inﬂammatory tonus of our
participants, shown by levels of CRP and PAI-I within the normal
range, makes it difﬁcult to demonstrate anti-inﬂammatory actions,
at least as effects on these markers of inﬂammation.
Although the mechanisms whereby rose hip lowers systolic
blood pressure and plasma cholesterol levels remain unresolved,
the ﬁndings of this study may have important health implications.
The current study could be the starting point for exploring rose
hip as a constituent of food portfolios aimed at reducing
cholesterol and blood pressure, and thereby decrease the risk of
coronary heart disease and mortality. Efﬁcient food portfolios are
urgently needed and they represent an attractive alternative to
statin treatment for people that, because of muscle pain and
increases in liver and muscle enzymes, do not tolerate statins, as
well as for people at risk of developing diabetes, as statins recently
were shown to increase the risk of diabetes.
30
Food portfolios designed to lower plasma cholesterol typically
contain soy, nuts or almonds, viscous ﬁber and plant sterols.
20,31 It
would be of interest to explore the potential additive and
synergistic effects of rose hip in such portfolios. Follow-up studies
of dietary treatment with rose hip should not only be performed
in hyperlipidemic and hypertensive individuals in order to study
its potency in lowering cholesterol and blood pressure in more
detail, but also in diabetic individuals in order to further explore its
possible antidiabetic effects.
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